滄州明珠(002108.SZ):公司隔膜產品已投產的生產線年設計產能合計為4.9億平方米
格隆匯11月28日丨滄州明珠(002108.SZ)在投資者互動平台表示,截至目前,公司隔膜產品已投產的生產線年設計產能合計為4.9億平方米。目前隔膜產品在建的產能有在蕪湖投資建設的年產2億平方米濕法隔膜項目以及在滄州投資建設的年產12億平方米濕法隔膜和年產5億平方米幹法隔膜項目;截至目前,公司已投產的BOPA薄膜生產線年設計產能合計為6.65萬噸,目前在建產能為3.8萬噸;PE管道產品年設計產能約20萬噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.